Poison Ivy, Oak, and Sumac Dermatitis: What Is Known and What Is New?
Publication: Dermatitis
Volume 30, Issue Number 3
Abstract
Poison ivy, poison oak, and poison sumac are the most common causes of clinically diagnosed allergic contact dermatitis in North America. Approximately 50% to 75% of the US adult population is clinically sensitive to poison ivy, oak, and sumac. We reviewed the botany and history of these plants; urushiol chemistry and pathophysiology, clinical features, and the prevalence of allergic contact dermatitis caused by these plants; and current postexposure treatment and preventive methods, including ongoing investigations in the development of a vaccine (immunotherapy). Although extensive efforts have been made to develop therapies that prevent and treat contact dermatitis to these plants, there lacks an entirely effective method, besides complete avoidance. There is a need for a better therapy to definitively prevent allergic contact dermatitis to these plants.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1. Marks JG. Poison ivy and poison oak allergic contact dermatitis. J Allergy Clin Immunol 1989;9:497–506.
2. Gladman AC. Toxicodendron dermatitis: poison ivy, oak, and sumac. Wilderness Environ Med 2006;17:120–128.
3. Boyd JE, Rucker J. A poisoned reputation. Chemical Heritage: Summer 2013. Available at: https://www.sciencehistory.org/distillations/magazine/no-ill-nature-the-surprising-history-and-science-of-poison-ivy-and-its.
4. Pariser DM, Ceilley RI, Lefkovits AM, et al. Poison ivy, oak and sumac. Derm Insights 2003;4:26–28.
5. Fisher AA. Poison ivy/oak/sumac. Part II: specific features. Cutis 1996;58:22–24.
6. Scappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat 13 2006;159:1–66.
7. Lewin Group. Burden of skin diseases. Society for Investigative Dermatology and American Academy of Dermatology Association, Cleveland 2005, 105 pp.
8. Fretwell S. Poison ivy cases on the rise. The State; 2017. Available at: https://www.thestate.com/news/local/article150403932.html.
9. Protecting workers from poisonous plants. Monthly safety unlimited newsletter. September 2014. Available at: http://www.safetyunlimited.com/blog/2014/09/default.aspx. Accessed January 3, 2019.
10. Flamm A, Zomorodi N, Maczunga S, et al. Characteristics of Toxicodendron Dermatitis in the United States. Poster presented at the American Contact Dermatitis Annual Meeting; 2019; Washington, DC.
11. Mohan JE, Ziska LH, Schlesinger WH, et al. Biomass and toxicity responses of poison ivy (Toxicodendron radicans) to elevated atmospheric CO2. PNAS 2006;103:9086–9089.
12. Marks JG, Anderson BE, DeLeo VA. Contact and Occupational Dermatology. New Delhi, India: Jaypee Brothers Medical Publishers (P) Ltd; 2016.
13. Dawson CR. The chemistry of poison ivy. Trans N Y Acad Sci 1956;18:427–443.
14. Valladeau J, Ravel O, Dezutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71–81.
15. Hanau D, Fabre M, Schmitt DA, et al. Human epidermal Langerhans cells cointernalize by receptor-mediated endocytosis “non-classical” major histocompatibility complex class I molecules (T6 antigens) and class II molecules (HLA-DR antigens). Proc Natl Acad Sci U S A 1987;84:2901–2905.
16. Hunger RE, Sieling PA, Ochoa MT, et al. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest 2004;113:701–708.
17. Kim JH, Hu Y, Yongqing T, et al. CD1a on Langerhans cells controls inflammatory skin diseases. Nat Immunol 2016;17(10):1159–1166.
18. Gayer KD, Burnett JW. Toxicodendron dermatitis. Cutis 1988;42(2):99–100.
19. Dunn IS, Liberato DJ, Castagnoli N, et al. Contact sensitivity to urushiol: role of covalent bond formation. Cell Immunol 1982;74(2):220–233.
20. Kligman AM. Poison ivy (Rhus) dermatitis. AMA Arch Derm 1958;77:149–180.
21. Williams JV, Light J, Marks JG. Individual variations in allergic contact dermatitis from urushiol. Arch Dermatol 1999;135:1002–1003.
22. Brook I, Frazier EH, Yeager JK. Microbiology of infected poison ivy dermatitis. Br J Dermatol 2000;142:943–946.
23. Hurwitz RM, Rivera HP, Guin JD. Black-spot poison ivy dermatitis. Am J Dermatopathol 1984;6(4):319–322.
24. Baer RL. Poison ivy dermatitis. Cutis 1990;46:34.
25. Wiliford PM, Sheretz EF. Poison ivy dermatitis. Nuances in treatment. Arch Fam Med 1995;3:184.
26. Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002;205:40.
27. Yospovitch G, Fleischer A. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Am J Clin Dermatol 2003;4:617.
28. Amrol D, Keitel D, Hagaman D, et al. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91(6):563–566.
29. Li LY, Cruz PD Jr. Allergic contact dermatitis: pathophysiology applied to future therapy. Dermatol Ther 2004;17:219–223.
30. Craig K, Meadows SE. What is the best duration of steroid therapy for contact dermatitis (Rhus)? J Fam Pract 2006;55:166–167.
31. Brodell RT, Williams L. Taking the itch out of poison ivy. Are you prescribing the right medication? Postgrad Med 1999;106:69.
32. Stibich AS, Yagan M, Sharma V, et al. Cost-effective post-exposure prevention of poison ivy dermatitis. Int J Dermatol 2000;39:515–518.
33. Davila A, Lucas J, Laurora M, et al. A new topical agent, Zanfel, ameliorates urushiol-induced Toxicodendron allergic contact dermatitis [abstract 364]. Ann Emerg Med 2003;42(Suppl 4):s98.
34. Long D, Ballentine NH, Marks JG. Treatment of poison ivy/oak allergic contact dermatitis with an extract of jewelweed. Am J Contact Dermat 1997;8(3):150–153.
35. Motz VA, Bowers CP, Kneubehl AR, et al. Efficacy of the saponin component of Impatiens capensis Meerb. In preventing urushiol-induced contact dermatitis. J Etnopharmacol 2015;162:163–167.
36. Marks JG Jr, Fowler JF Jr, Sheretz EF, et al. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite. J Am Acad Dermatol 1995;33:212–216.
37. Orchard S, Fellman JH, Storrs FJ. Poison ivy/oak dermatitis. Use of polyamine salts of a linoleic acid dimer for topical prophylaxis. Arch Dermatol 1986;122:783–789.
38. Grevelink SA, Murrell DF, Olsen EA. Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis. J Am Acad Dermatol 1922;27:182–188.
39. Signore RJ. Prevention of poison ivy dermatitis with oral homeopathic Rhus Toxicodendron. Dermatology Online J 2017;23:17.
40. Gross ER. An oral antigen preparation in the prevention of poison ivy dermatitis; results in 455 cases of ivy sensitivity. Ind Med Surg 1958;27(3):142–144.
41. Stein MF, Parsons E. Effectiveness in oral Rhus tox solution for poison ivy prevention. Int J Pharm Compd 2003;7(4):272–275.
42. Marks JG Jr, Trautlein JJ, Epstein WL, et al. Oral hyposensitzation to poison ivy and poison oak. Arch Dermatol 1987;123:476–478.
43. Motz VA, Bowers CP, Young LM, et al. The effectiveness of jewelweed, Impatiens capensis, the related cultivar l. balsamina and the component, lawsone in preventing post poison ivy exposure contact dermatitis. J Ethnopharmacol 2012;143:314–318.
44. Epstein WL, Baer H, Dawson CR, et al. Poison oak hyposensitization. Evaluation of purified urushiol. Arch Dermatol 1974;109:356–360.
45. Neill BC, Neill JA, Brauker J, et al. Post-exposure prevention of Toxicodendron dermatitis with early forceful unidirectional washing. J Am Acad Dermatol 2018.
46. Epstein WL. Rhus dermatitis. Ped Clinics of North Am 1959;843–852.
47. Orchard S, Fellman JH, Storrs FJ. Poison ivy/oak dermatitis. Use of polyamine salts of a linoleic acid dimer for topical prophylaxis. Arch Dermatol 1986;122:783–789.
48. Grevelink SA, Murrell DF, Olsen EA. Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis. J Am Acad Dermatol 1992;27:182.
49. Dakin R. Remarks on a cutaneous affection produced by certain poisonous vegetables. Am J M sc. 1829;4:98–100.
50. Duncan CH. Autotherapy in ivy poisoning. NY Med J 1916;104:901.
51. Epstein WL, Baer H, Dawson CR, et al. Poison oak hyposensitization. Arch Dermatol 1974;109:356–360.
52. Reginella RF, Fairfield JC, Marks JG Jr. Hyposensitization to poison ivy after working in a cashew nut shell oil processing factory. Contact Dermatitis 1989;20:274–279.
53. ElSohly MA, Gul W, Abdel-Bakky MS, et al. Compositions for prevention/prophylactic treatment of poison ivy dermatitis. J Sci Med Central 2018;6:1115.
54. Kim Y, Longenecker A, ElSohly MA, et al. Urushiol patch test using the T.R.U.E. test system. Dermatitis 2018;29:127–131.
